Arcturus Therapeutics Holdings Inc (ARCT)

Feb 20, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Down 9.9% in January - MarketBeat

Feb 20, 2025

Feb 19, 2025

Empire Life Investments Inc. Purchases 128,771 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Feb 19, 2025

Feb 18, 2025

HC Wainwright Reaffirms Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT) - MarketBeat

Feb 18, 2025

Feb 16, 2025

The week in pharma: action, reaction and insight – week to February 14 - The Pharma Letter

Feb 16, 2025

Feb 16, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $65.00 Consensus Target Price from Analysts - Defense World

Feb 16, 2025

Feb 16, 2025

Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $65.00 - MarketBeat

Feb 16, 2025

Feb 16, 2025

HC Wainwright Reaffirms “Buy” Rating for Arcturus Therapeutics (NASDAQ:ARCT) - Defense World

Feb 16, 2025

Feb 16, 2025

Sumitomo Mitsui Trust Group Inc. Has $35.04 Million Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Feb 16, 2025

Feb 15, 2025

EC approves CSL and Arcturus’ Kostaive - The Pharma Letter

Feb 15, 2025

Feb 15, 2025

CSL and Arcturus Therapeutics Announces Marketing Authorization Grant by European Commission Marketing Authorization for Kostaive (Arct-154), A Self-Amplifying Mrna Covid-19 Vaccine - Marketscreener.com

Feb 15, 2025

Feb 14, 2025

Breaking Down Arcturus Therapeutics: 5 Analysts Share Their Views - Benzinga

Feb 14, 2025

Feb 14, 2025

ARCTArcturus Therape Latest Stock News & Market Updates - StockTitan

Feb 14, 2025

Feb 14, 2025

Arcturus Therapeutics Says EU Commission Approves COVID-19 Vaccine Kostaive - Marketscreener.com

Feb 14, 2025

Feb 14, 2025

EU Grants Marketing Authorization For KOSTAIVE To CSL And Arcturus Therapeutics - Nasdaq

Feb 14, 2025

Feb 14, 2025

Revolutionary COVID Vaccine Breakthrough: New Technology Shows Year-Long Immunity in EU Approval - StockTitan

Feb 14, 2025

Feb 14, 2025

Revolutionary COVID Vaccine Breakthrough: EU Approves KOSTAIVE with Year-Long Immunity Power - StockTitan

Feb 14, 2025

Feb 14, 2025

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - The Malaysian Reserve

Feb 14, 2025

Feb 13, 2025

Selling Arcturus Therapeutics Holdings Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St

Feb 13, 2025

Feb 08, 2025

SG Americas Securities LLC Has $203,000 Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Feb 08, 2025

Feb 05, 2025

Arcturus Therapeutics names Moncef Slaoui as Chair Designate - MSN

Feb 05, 2025

Feb 05, 2025

State Street Corp Reduces Holdings in Arcturus Therapeutics Holdings Inc - GuruFocus.com

Feb 05, 2025

Feb 05, 2025

Arcturus Therapeutics names Moncef Slaoui as Chair Designate By Investing.com - Investing.com Australia

Feb 05, 2025

Feb 05, 2025

Short Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Increases By 8.6% - MarketBeat

Feb 05, 2025

Feb 04, 2025

Global mRNA Vaccines and Therapeutics Market is expected - openPR

Feb 04, 2025

Feb 04, 2025

Arcturus Therapeutics Appoints Moncef Slaoui Chair Designate -February 04, 2025 at 10:40 am EST - Marketscreener.com

Feb 04, 2025

Feb 04, 2025

Arcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal year - MSN

Feb 04, 2025

Feb 04, 2025

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate - Business Wire

Feb 04, 2025

Jan 31, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at BTIG Research - MarketBeat

Jan 31, 2025

Jan 31, 2025

Japan's COVID Vaccine Independence: Meiji Gets Green Light for Local KOSTAIVE Production - StockTitan

Jan 31, 2025

Jan 30, 2025

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference - BioSpace

Jan 30, 2025

Jan 30, 2025

BTIG Research Begins Coverage on Arcturus Therapeutics (NASDAQ:ARCT) - Defense World

Jan 30, 2025

Jan 29, 2025

ARCT (Arcturus Therapeutics Holdings) Cash-to-Debt : 8.06 (As of Sep. 2024) - GuruFocus.com

Jan 29, 2025

Jan 28, 2025

BTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy Recommendation - Nasdaq

Jan 28, 2025

Jan 28, 2025

Arcturus: Downgrading As mRNA Promise Meets Market Reality (NASDAQ:ARCT) - Seeking Alpha

Jan 28, 2025

Jan 28, 2025

Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews - Benzinga

Jan 28, 2025

Jan 28, 2025

BTIG Initiates Arcturus Therapeutics Holdings at Buy With $41 Price Target -January 28, 2025 at 07:27 am EST - Marketscreener.com

Jan 28, 2025

Jan 27, 2025

Arcturus Therapeutics to Present at the Investor Summit on December 17th in Philadelphia. - ACCESS Newswire

Jan 27, 2025

Jan 25, 2025

Leerink Partnrs Has Positive Outlook of ARCT FY2024 Earnings - Defense World

Jan 25, 2025

Jan 24, 2025

What is Leerink Partnrs' Forecast for ARCT FY2024 Earnings? - MarketBeat

Jan 24, 2025

Jan 24, 2025

Cantor Fitzgerald Forecasts ARCT FY2025 Earnings - Defense World

Jan 24, 2025

Jan 24, 2025

Q3 Earnings Estimate for ARCT Issued By Leerink Partnrs - Defense World

Jan 24, 2025

Jan 23, 2025

Q3 Earnings Forecast for ARCT Issued By Leerink Partnrs - MarketBeat

Jan 23, 2025

Jan 22, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Target Price from Analysts - Defense World

Jan 22, 2025

Jan 21, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Significant Increase in Short Interest - Defense World

Jan 21, 2025